{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:47:18Z","timestamp":1793832438583,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Clinical Research from the National Hospital Organization","award":["H28-NHO(Shinkei)-01"],"award-info":[{"award-number":["H28-NHO(Shinkei)-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transient receptor potential cation channel subfamily V member 2 (TRPV2) functions as a stretch-sensitive calcium channel, with overexpression in the sarcolemma of skeletal and cardiac myocytes leading to detrimental calcium influx and triggering muscle degeneration. In our previous pilot study, we showed that tranilast, a TRPV2 inhibitor, reduced brain natriuretic peptide levels in two patients with muscular dystrophy and advanced heart failure. Building on this, we performed a single-arm, open-label, multicenter study herein to evaluate the safety and efficacy of tranilast in the treatment of advanced heart failure in patients with muscular dystrophy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study involved 18 patients with muscular dystrophy who had brain natriuretic peptide levels\u2009&gt;\u2009100 pg\/mL, despite receiving standard cardioprotective therapy. Tranilast was administered orally at a dose of 100\u00a0mg three times daily. Over the short-term period (28 weeks), the primary endpoint of change ratio in the logarithm of brain natriuretic peptide level from baseline to 28 weeks was not significant in the full analysis set but was lower in the per set protocol compared with data from a previous beta-blocker treatment study. All 15 patients who completed the short-term treatment consented to be enrolled in long-term therapy for an additional 116 weeks. After all participants completed the long-term treatment, we analyzed all data. TRPV2 expression on the peripheral blood mononuclear cell surfaces decreased throughout the study period, confirming that the TRPV2 inhibitory effect of tranilast was maintained over time. Despite the presence of progressive disease, cardiac indices such as brain natriuretic peptide level, human atrial natriuretic peptide level, and fractional shortening, remained stable, and only brain natriuretic peptide levels at 144 weeks showed significant changes. The survival rate was 80.7%, and no cardiac deaths were reported. Regarding safety, no serious adverse events associated with tranilast were noted, except for recurrent diarrhea during the short-term period in one case.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings suggest that tranilast can inhibit TRPV2 expression for an extended period and is effective in preventing the worsening of cardiac function and subsequent death from heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration details<\/jats:title>\n                    <jats:p>\n                      The study was registered in the UMIN Clinical Trials Registry (UMIN-CTR: UMIN000031965, URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.umin.ac.jp\/ctr\/\">http:\/\/www.umin.ac.jp\/ctr\/<\/jats:ext-link>\n                      ) [March 30, 2018] and the Japan Registry of Clinical Trials (jRCT, registration number: jRCTs031180038, URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\/\">https:\/\/jrct.niph.go.jp\/<\/jats:ext-link>\n                      ) [November 12, 2021]. Patient registration was initiated on December 19, 2018.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03538-1","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:47:23Z","timestamp":1736416043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of tranilast in preventing exacerbating cardiac function and death from heart failure in muscular dystrophy patients with advanced-stage heart failure: a single-arm, open-label, multicenter study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6241-3626","authenticated-orcid":false,"given":"Tsuyoshi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Fukudome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Motoyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruriko","family":"Kitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhisa","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sekimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"3538_CR1","doi-asserted-by":"publisher","unstructured":"Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku. 2011;51. https:\/\/doi.org\/10.5692\/clinicalneurol.51.743. 743\u2009\u2013\u200950 [Japanese].","DOI":"10.5692\/clinicalneurol.51.743"},{"key":"3538_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"key":"3538_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/01.RES.0000097263.10220.0C","volume":"93","author":"K Muraki","year":"2003","unstructured":"Muraki K, Iwata Y, Katanosaka Y, Ito T, Ohya S, Shigekawa M, et al. TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res. 2003;93:829\u201338. https:\/\/doi.org\/10.1161\/01.RES.0000097263.10220.0C","journal-title":"Circ Res"},{"key":"3538_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1083\/jcb.200301101","volume":"161","author":"Y Iwata","year":"2003","unstructured":"Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor\u2013regulated channel. J Cell Biol. 2003;161:957\u201367. https:\/\/doi.org\/10.1083\/jcb.200301101","journal-title":"J Cell Biol"},{"key":"3538_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/cvr\/cvt163","volume":"99","author":"Y Iwata","year":"2013","unstructured":"Iwata Y, Ohtake H, Suzuki O, Matsuda J, Komamura K, Wakabayashi S. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy. Cardiovasc Res. 2013;99:760\u20138. https:\/\/doi.org\/10.1093\/cvr\/cvt163","journal-title":"Cardiovasc Res"},{"key":"3538_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bcp.2005.05.034","volume":"70","author":"Y Iwata","year":"2005","unstructured":"Iwata Y, Katanosaka Y, Shijun Z, Kobayashi Y, Hanada H, Shigekawa M, et al. Protective effects of Ca2\u2009+\u2009handling drugs against abnormal Ca2\u2009+\u2009homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol. 2005;70:740\u201351. https:\/\/doi.org\/10.1016\/j.bcp.2005.05.034","journal-title":"Biochem Pharmacol"},{"key":"3538_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/hmg\/ddn408","volume":"18","author":"Y Iwata","year":"2009","unstructured":"Iwata Y, Katanosaka Y, Arai Y, Shigekawa M, Wakabayashi S. Dominant-negative inhibition of Ca2\u2009+\u2009influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum Mol Genet. 2009;18:824\u201334. https:\/\/doi.org\/10.1093\/hmg\/ddn408","journal-title":"Hum Mol Genet"},{"key":"3538_CR8","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1016\/j.febslet.2009.10.033","volume":"583","author":"N Zanou","year":"2009","unstructured":"Zanou N, Iwata Y, Schakman O, Lebacq J, Wakabayashi S, Gailly P. Essential role of TRPV2 ion channel in the sensitivity of dystrophic muscle to eccentric contractions. FEBS Lett. 2009;583:3600\u20134. https:\/\/doi.org\/10.1016\/j.febslet.2009.10.033","journal-title":"FEBS Lett"},{"key":"3538_CR9","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.18632\/oncotarget.24449","volume":"9","author":"Y Iwata","year":"2018","unstructured":"Iwata Y, Katayama Y, Okuno Y, Wakabayashi S. Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model. Oncotarget. 2018;9:14042\u201357. https:\/\/doi.org\/10.18632\/oncotarget.24449","journal-title":"Oncotarget"},{"key":"3538_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2169\/internalmedicine.8651-16","volume":"57","author":"T Matsumura","year":"2018","unstructured":"Matsumura T, Matsui M, Iwata Y, Asakura M, Saito T, Fujimura H, et al. A pilot study of tranilast for cardiomyopathy of muscular dystrophy. Intern Med. 2018;57:311\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.8651-16","journal-title":"Intern Med"},{"key":"3538_CR11","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.3390\/ijms20163844","volume":"20","author":"Y Iwata","year":"2019","unstructured":"Iwata Y, Matsumura T. Blockade of TRPV2 is a novel therapy for cardiomyopathy in muscular dystrophy. Int J Mol Sci. 2019;20:3844. https:\/\/doi.org\/10.3390\/ijms20163844","journal-title":"Int J Mol Sci"},{"key":"3538_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2739\/kurumemedj.MS662006","volume":"66","author":"T Matsumura","year":"2021","unstructured":"Matsumura T, Hashimoto H, Sekimizu M, Saito AM, Iwata Y, Asakura M, et al. Study protocol for a multicenter, open-label, single-arm study of tranilast for cardiomyopathy of muscular dystrophy. Kurume Med J. 2021;66:121\u20136. https:\/\/doi.org\/10.2739\/kurumemedj.MS662006","journal-title":"Kurume Med J"},{"key":"3538_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","volume":"25","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart failure society. Eur J Heart Fail. 2023;25:616\u201331. https:\/\/doi.org\/10.1002\/ejhf.2848","journal-title":"Eur J Heart Fail"},{"key":"3538_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ehjqcco\/qcaa059","volume":"7","author":"A Nikhanj","year":"2021","unstructured":"Nikhanj A, Nichols BM, Wang K, Siddiqi ZA, Oudit GY. Evaluating the diagnostic and prognostic value of biomarkers for heart disease and major adverse cardiac events in patients with muscular dystrophy. Eur Heart J Qual Care Clin Outcomes. 2021;7:564\u201373. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaa059","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"3538_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.nmd.2004.08.002","volume":"14","author":"J Demachi","year":"2004","unstructured":"Demachi J, Kagaya Y, Watanabe J, Sakuma M, Ikeda J, Kakuta Y, et al. Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromuscul Disord. 2004;14:732\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2004.08.002","journal-title":"Neuromuscul Disord"},{"key":"3538_CR16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2169\/internalmedicine.49.3259","volume":"49","author":"T Matsumura","year":"2010","unstructured":"Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med. 2010;49:1357\u201363. https:\/\/doi.org\/10.2169\/internalmedicine.49.3259","journal-title":"Intern Med"},{"key":"3538_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13023-022-02352-3","volume":"17","author":"T Matsumura","year":"2022","unstructured":"Matsumura T, Hashimoto H, Sekimizu M, Saito AM, Motoyoshi Y, Nakamura A, et al. Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study. Orphanet J Rare Dis. 2022;17:201. https:\/\/doi.org\/10.1186\/s13023-022-02352-3","journal-title":"Orphanet J Rare Dis"},{"key":"3538_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5692\/clinicalneurol.52.211","volume":"52","author":"T Matsumura","year":"2012","unstructured":"Matsumura T, Saito T, Fujimura H, Sakoda S. Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy. Rinsho Shinkeigaku. 2012;52:211\u20137. https:\/\/doi.org\/10.5692\/clinicalneurol.52.211. [Japanese].","journal-title":"Rinsho Shinkeigaku"},{"key":"3538_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/mus.26757","volume":"61","author":"T Motoki","year":"2020","unstructured":"Motoki T, Shimizu-Motohashi Y, Saito I, Komaki H, Ishiyama A, Aibara K, et al. Renal dysfunction can occur in advanced-stage Duchenne muscular dystrophy. Muscle Nerve. 2020;61:192\u20137. https:\/\/doi.org\/10.1002\/mus.26757","journal-title":"Muscle Nerve"},{"key":"3538_CR20","doi-asserted-by":"publisher","first-page":"e0177132","DOI":"10.1371\/journal.pone.0177132","volume":"12","author":"M Entin-Meer","year":"2017","unstructured":"Entin-Meer M, Cohen L, Hertzberg-Bigelman E, Levy R, Ben-Shoshan J, Keren G. TRPV2 knockout mice demonstrate an improved cardiac performance following myocardial infarction due to attenuated activity of peri-infarct macrophages. PLoS ONE. 2017;12:e0177132. https:\/\/doi.org\/10.1371\/journal.pone.0177132","journal-title":"PLoS ONE"},{"key":"3538_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/jcdd6040034","volume":"6","author":"J Feng","year":"2019","unstructured":"Feng J, Armillei MK, Yu AS, Liang BT, Runnels LW, Yue L. Ca2\u2009+\u2009signaling in cardiac fibroblasts and fibrosis-associated heart diseases. J Cardiovasc Dev Dis. 2019;6:34. https:\/\/doi.org\/10.3390\/jcdd6040034","journal-title":"J Cardiovasc Dev Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03538-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03538-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03538-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T10:05:45Z","timestamp":1736417145000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03538-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3538"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03538-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3871484\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Review Board of National Hospital Organization Osaka Toneyama Medical Center (approval number: TNH-R-2023031). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}